Earlier, expanded insulin use leading to uphill battle for newer drugs
October 14, 2009
My client, Scientia Advisors, says that diabetes care is undergoing a paradigm shift in which insulin is being prescribed earlier, for more conditions, in order to delay the onset of full-blown disease. In a study released today, the global management consulting firm finds that as more drugs go generic, companies offering newer, more expensive drugs will face resistance in markets most constrained by economics.
Harry Glorikian, Scientia Advisors’ managing partner, said: “While there are exciting developments in the non-insulin oral drug categories, the makers of these newer medications would be wise to stay attuned to how to best position their products—especially when marketing in emerging economies, which are extremely sensitive to costs.”
Scientia Advisors is a global management consulting firm specializing in growth strategies for major and emerging companies.
Glorikian said: “We expect that as more drugs become available in generic form, incretin mimetics (which increase insulin secretion) and insulins will generate an increasing share of the revenues. Therapies with benefits beyond glucose management (such as delaying the onset of diabetes or treating co-morbid conditions) will be used earlier in treatment. For a variety of reasons, “
The study outlines basic scientific facts about diabetes, diabetes markets in different parts of the world, and mechanisms of action for various diabetes medications.
It predicts growth and revenue share for individual drugs and describes the ways in which “players” and a changing treatment paradigm are affected by traditional, emerging and future drugs and technologies. The study also analyzes how alternative delivery methods (needle-free injection; intranasal, inhaled, dermal, buccal, rectal and new oral methods) will impact insulin usage.
The study, funded by Scientia itself, is based on extensive primary and secondary research and proprietary analytic methods. It’s available for download from Scientia’s Web site at www.scientiaadv.com.
—Anita M. Harris
HarrisComBlog is a publication of the Harris Communications Group of Cambridge, MA. We also publish New Cambridge Observer.
